Abstract
Understanding the molecular events that commit to the cell cycle has important implications for cancer. Available evidence, mostly derived from human tumors, has revealed frequent alterations in genes involved in the control of the G1 restriction point and the progression from G1 to S phase. Many of the players that participate in these events have been characterized at the biochemical level. They include, among others the cyclin-dependent kinases (Cdk), Cdk4, Cdk6 and Cdk2 and their cognate D- and E-type cyclins, Cdk inhibitors (CKI), and the main Cdk downstream substrates, the retinoblastoma (pRb) family of proteins. Yet, there is little information as how these molecules regulate cell cycle commitment in vivo. The development of mouse strains carrying targeted mutations in these loci is opening new ways to explore the network of molecular pathways that control passage through G1 into the S phase in complex multicellular organisms such as mammals. These strains are also providing new insights as of how misregulation of these processes may lead to cancer development. In this review, we attempt to summarize our current knowledge of the molecular mechanisms that control the G1 / S transition with particular emphasis in those studies carried out in vivo using gene targeted mice.
Keywords: gi restriction, transition, cdk inhibitor, cdku,cdk6, cdk2
Current Genomics
Title: Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Volume: 3 Issue: 4
Author(s): S. Ortega, M. Malumbres and M. Barbacid
Affiliation:
Keywords: gi restriction, transition, cdk inhibitor, cdku,cdk6, cdk2
Abstract: Understanding the molecular events that commit to the cell cycle has important implications for cancer. Available evidence, mostly derived from human tumors, has revealed frequent alterations in genes involved in the control of the G1 restriction point and the progression from G1 to S phase. Many of the players that participate in these events have been characterized at the biochemical level. They include, among others the cyclin-dependent kinases (Cdk), Cdk4, Cdk6 and Cdk2 and their cognate D- and E-type cyclins, Cdk inhibitors (CKI), and the main Cdk downstream substrates, the retinoblastoma (pRb) family of proteins. Yet, there is little information as how these molecules regulate cell cycle commitment in vivo. The development of mouse strains carrying targeted mutations in these loci is opening new ways to explore the network of molecular pathways that control passage through G1 into the S phase in complex multicellular organisms such as mammals. These strains are also providing new insights as of how misregulation of these processes may lead to cancer development. In this review, we attempt to summarize our current knowledge of the molecular mechanisms that control the G1 / S transition with particular emphasis in those studies carried out in vivo using gene targeted mice.
Export Options
About this article
Cite this article as:
Ortega S., Malumbres M. and Barbacid M., Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition, Current Genomics 2002; 3 (4) . https://dx.doi.org/10.2174/1389202023350444
DOI https://dx.doi.org/10.2174/1389202023350444 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Recent Patents on MicroRNA-Induced Pluripotent Stem Cell Generation
Recent Patents on Regenerative Medicine Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry PEDF in Angiogenic Eye Diseases
Current Molecular Medicine The Pathogenesis of Susceptibility to Acute Kidney Injury in the Elderly
Current Aging Science n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Editorial (Hot Topic: Network Pharmacology: An Emerging Field in Cancer Drug Discovery)
Current Drug Discovery Technologies